Amgen drug gets boost in fiscal cliff legislation THE BRAND NEW York Times: Medicare Prices Delay Is Political Win For Drug Maker Just fourteen days after pleading guilty in a significant federal fraud case, Amgen, the world's largest biotechnology company, scored a generally unnoticed coup on Capitol Hill: Lawmakers inserted a paragraph in to the ‘fiscal cliff’ bill that didn’t mention the business by name but strongly favored among its drugs. The language buried in Section 632 of regulations delays a set of Medicare cost restraints on a class of drugs which includes Sensipar, a lucrative Amgen pill utilized by kidney dialysis sufferers . This article was reprinted from kaiserhealthnews minoxidil vs finasteride hair loss .org with permission from the Henry J.